Literature DB >> 25844122

Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes.

Toshimitsu Hamasaki1, Koko Asakura1, Scott R Evans2, Tomoyuki Sugimoto3, Takashi Sozu4.   

Abstract

We discuss the decision-making frameworks for clinical trials with multiple co-primary endpoints in a group-sequential setting. The decision-making frameworks can account for flexibilities such as a varying number of analyses, equally or unequally spaced increments of information and fixed or adaptive Type I error allocation among endpoints. The frameworks can provide efficiency, i.e., potentially fewer trial participants, than the fixed sample size designs. We investigate the operating characteristics of the decision-making frameworks and provide guidance on constructing efficient group-sequential strategies in clinical trials with multiple co-primary endpoints.

Entities:  

Keywords:  Adaptive Type I error allocation; Average sample number; Hierarchical testing procedure; Maximum sample size; equally or unequally spaced increments of information

Year:  2015        PMID: 25844122      PMCID: PMC4382106          DOI: 10.1080/19466315.2014.1003090

Source DB:  PubMed          Journal:  Stat Biopharm Res        ISSN: 1946-6315            Impact factor:   1.452


  19 in total

1.  Modification of sample size in group sequential clinical trials.

Authors:  L Cui; H M Hung; S J Wang
Journal:  Biometrics       Date:  1999-09       Impact factor: 2.571

2.  A convenient formula for sample size calculations in clinical trials with multiple co-primary continuous endpoints.

Authors:  Tomoyuki Sugimoto; Takashi Sozu; Toshimitsu Hamasaki
Journal:  Pharm Stat       Date:  2012 Mar-Apr       Impact factor: 1.894

3.  Sample size determination in clinical trials with multiple co-primary binary endpoints.

Authors:  Takashi Sozu; Tomoyuki Sugimoto; Toshimitsu Hamasaki
Journal:  Stat Med       Date:  2010-09-20       Impact factor: 2.373

4.  Method of balanced adjustment in testing co-primary endpoints.

Authors:  George Kordzakhia; Ohidul Siddiqui; Mohammad F Huque
Journal:  Stat Med       Date:  2010-08-30       Impact factor: 2.373

5.  Hierarchical testing of multiple endpoints in group-sequential trials.

Authors:  Ekkehard Glimm; Willi Maurer; Frank Bretz
Journal:  Stat Med       Date:  2010-01-30       Impact factor: 2.373

6.  Sample size determination in superiority clinical trials with multiple co-primary correlated endpoints.

Authors:  Takashi Sozu; Tomoyuki Sugimoto; Toshimitsu Hamasaki
Journal:  J Biopharm Stat       Date:  2011-07       Impact factor: 1.051

7.  A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints.

Authors:  Tomoyuki Sugimoto; Takashi Sozu; Toshimitsu Hamasaki; Scott R Evans
Journal:  Biostatistics       Date:  2013-01-10       Impact factor: 5.899

8.  Sample size determination in group-sequential clinical trials with two co-primary endpoints.

Authors:  Koko Asakura; Toshimitsu Hamasaki; Tomoyuki Sugimoto; Kenichi Hayashi; Scott R Evans; Takashi Sozu
Journal:  Stat Med       Date:  2014-03-27       Impact factor: 2.373

9.  A multiple testing procedure for clinical trials.

Authors:  P C O'Brien; T R Fleming
Journal:  Biometrics       Date:  1979-09       Impact factor: 2.571

10.  Sample size determination for clinical trials with co-primary outcomes: exponential event times.

Authors:  Toshimitsu Hamasaki; Tomoyuki Sugimoto; Scott Evans; Takashi Sozu
Journal:  Pharm Stat       Date:  2012-10-19       Impact factor: 1.894

View more
  11 in total

1.  Exact sequential analysis for multiple weighted binomial end points.

Authors:  Ivair R Silva; Joshua J Gagne; Mehdi Najafzadeh; Martin Kulldorff
Journal:  Stat Med       Date:  2019-11-25       Impact factor: 2.373

Review 2.  Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.

Authors:  Toshimitsu Hamasaki; Scott R Evans; Koko Asakura
Journal:  J Biopharm Stat       Date:  2017-10-30       Impact factor: 1.051

3.  Incorporating biomarkers to improve statistical power of immunotherapeutic neoadjuvant clinical trials in patients with triple-negative breast cancer.

Authors:  Feng Gao; Guoqiao Wang; Jingqin Luo; Jingxia Liu; Ling Chen; Chengjie Xiong
Journal:  Stat Biopharm Res       Date:  2019-04-18       Impact factor: 1.452

4.  Group-sequential three-arm noninferiority clinical trial designs.

Authors:  Toshimitsu Ochiai; Toshimitsu Hamasaki; Scott R Evans; Koko Asakura; Yuko Ohno
Journal:  J Biopharm Stat       Date:  2016-02-18       Impact factor: 1.051

5.  Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes.

Authors:  Tomoyuki Sugimoto; Toshimitsu Hamasaki; Scott R Evans; Susan Halabi
Journal:  Lifetime Data Anal       Date:  2019-04-12       Impact factor: 1.588

6.  Fundamentals and Catalytic Innovation: The Statistical and Data Management Center of the Antibacterial Resistance Leadership Group.

Authors:  Jacqueline Huvane; Lauren Komarow; Carol Hill; Thuy Tien T Tran; Carol Pereira; Susan L Rosenkranz; Matt Finnemeyer; Michelle Earley; Hongyu Jeanne Jiang; Rui Wang; Judith Lok; Scott R Evans
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

7.  Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints.

Authors:  Koko Asakura; Toshimitsu Hamasaki; Scott R Evans
Journal:  Biom J       Date:  2016-10-19       Impact factor: 2.207

8.  Interim Monitoring for Futility in Clinical Trials with Two Co-primary Endpoints Using Prediction.

Authors:  Koko Asakura; Scott R Evans; Toshimitsu Hamasaki
Journal:  Stat Biopharm Res       Date:  2019-11-04       Impact factor: 1.452

9.  On selecting the critical boundary functions in group-sequential trials with two time-to-event outcomes.

Authors:  Toshimitsu Hamasaki; H M James Hung; Chin-Fu Hsiao; Scott R Evans
Journal:  Contemp Clin Trials       Date:  2020-12-09       Impact factor: 2.226

10.  Choice of futility boundaries for group sequential designs with two endpoints.

Authors:  Svenja Schüler; Meinhard Kieser; Geraldine Rauch
Journal:  BMC Med Res Methodol       Date:  2017-08-08       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.